Meropenem vs Ertapenem in Pneumonia
For hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), meropenem is the appropriate carbapenem choice, while ertapenem is NOT indicated and should not be used.
Key Differences in Indications
Meropenem for HAP/VAP
Meropenem is explicitly recommended in the 2016 IDSA/ATS guidelines for empirical treatment of both HAP and VAP 1. The guidelines list meropenem 1 g IV q8h as a standard option across all risk categories of HAP, including patients at high risk of mortality and those requiring double antipseudomonal coverage.
Ertapenem NOT for HAP/VAP
Ertapenem is FDA-approved only for community-acquired pneumonia (CAP), NOT for hospital-acquired or ventilator-associated pneumonia 2. The FDA label specifically states ertapenem is indicated for CAP due to Streptococcus pneumoniae (penicillin-susceptible only), Haemophilus influenzae (beta-lactamase negative only), or Moraxella catarrhalis—organisms that cause community infections, not nosocomial pneumonia.
Critical Antimicrobial Coverage Differences
Why Ertapenem Fails in HAP/VAP
Ertapenem lacks activity against Pseudomonas aeruginosa and has limited activity against Enterococcus species 3. This is a fatal flaw for HAP/VAP treatment because:
- P. aeruginosa is a major pathogen in nosocomial pneumonia, particularly in ventilated patients
- The 2016 IDSA/ATS guidelines emphasize antipseudomonal coverage as essential for HAP/VAP empirical therapy 1
- Pharmacodynamic modeling demonstrates ertapenem has inappropriately low probabilities of target attainment for HAP pathogens, with one study showing ertapenem among the "lowest wCFR values" and concluding it would be "inappropriate as monotherapy" for HAP 4
Meropenem's Appropriate Spectrum
Meropenem provides:
- Robust antipseudomonal activity
- Broad coverage against ESBL-producing and AmpC-producing Enterobacteriaceae
- Activity against methicillin-susceptible Staphylococcus aureus (MSSA)
- Coverage of anaerobes
This spectrum matches the pathogen profile of HAP/VAP 5, 3.
Dosing Recommendations
For HAP (Non-VAP)
- Meropenem 1 g IV q8h 1
- Use across all risk categories: low mortality risk without MRSA factors, MRSA risk factors present, or high mortality risk
- Consider extended infusions for pharmacodynamic optimization
For VAP
- Meropenem 1 g IV q8h 1
- Often requires combination with a second antipseudomonal agent from a different class (fluoroquinolone or aminoglycoside) in high-risk patients
- Plus MRSA coverage (vancomycin or linezolid) when risk factors present
Ertapenem Dosing (CAP Only)
- 1 g IV once daily for community-acquired pneumonia 2
- The once-daily convenience is irrelevant when the drug lacks appropriate coverage for the infection
Common Pitfalls to Avoid
Do not use ertapenem for HAP/VAP simply because it's a carbapenem—the lack of antipseudomonal activity makes it inappropriate regardless of other carbapenem-class benefits
Do not assume "carbapenem coverage" is interchangeable—ertapenem's narrower spectrum is intentional for outpatient and community infections, not nosocomial pneumonia 3
Recognize that ertapenem's 4-hour half-life enabling once-daily dosing is a pharmacokinetic advantage only when the spectrum is appropriate 3—convenience cannot override inadequate coverage
In critically ill patients with hypoalbuminemia, even when treating non-pneumonia ESBL infections, ertapenem shows higher rates of antibiotic escalation 6, suggesting potential inadequacy in severe illness
Clinical Context
Meropenem has demonstrated efficacy in clinical trials specifically for HAP, including a multicenter trial showing 74% satisfactory clinical response at end of treatment and 68% response in VAP patients 7. Ertapenem has never been studied or approved for these indications 2, 8.
The bottom line: Use meropenem for HAP/VAP. Ertapenem is reserved for CAP and other community-acquired infections where Pseudomonas is not a concern.